Grand Pharmaceutical Group Limited announced that the Investigational New Drug application in China of the Group's global innovative ophthalmic drug GPN00884 for the delay of progression of myopia in children, was officially accepted by the National Medical Products Administration of the People's Republic of China recently. This study is a randomized, double-blind, placebo-controlled, and dose-escalating Phase I clinical trial, planning to enroll 40 healthy subjects to evaluate the safety, tolerability and pharmacokinetic features of GPN00884 eye drops in healthy subjects after single and multiple dosing. GPN00884 eye drops are an innovative drug with a new mechanism used to delay the progression of myopia in children.

Compared with low-concentration atropine eye drops, GPN00884 eye drops have no mydriasis effect, no adverse reactions such as photophobia and decreased accommodation, and the dosing period is not limited, which can improve patient compliance. At present, there is still a lack of drugs with clear efficacy and safety in terms of delaying the progression of myopia in Children and Adolescents, and the prevention and control of myopia has become one of the national strategies. Driven by the large number of patients, the clinical and market demand for myopia treatment products will continue to expand.

As one of the major ophthalmic drug R&D, production and sales integrated enterprises in China, the Group has nearly 30 ophthalmic products, mainly focusing on major indications such as dry eye, retinal hemorrhage, glaucoma, cataract, anti-inflammation and myopia, covering chemical preparations, Chinese drug preparations and eye health products, including prescription drugs, OTC drugs, medical devices, consumer goods and other major categories, creating a " public eye care ecosystem" by integrating "prevention + treatment + health care". In terms of innovation and R&D, the Group has reserved a few world-wide innovative products for the treatment of "myopia", "dry eye", "pterygium" and "anti-inflammatory and analgesic after ophthalmology surgery". Among them, the innovative product CBT-001 for the treatment of pterygium was approved to conduct Phase III clinical study in China in March this year; GPN00136 (BRM421), a small molecule peptide drug for the treatment of dry eye, was approved to conduct Phase II clinical study in China in April this year; GPN00833, a hormone nanosuspension eye drops for anti-inflammatory and analgesic, has completed first patient's enrollment and dosing in Phase III clinical trial in China in October this year.

In the future, the field will adhere to the development strategy of "leading by the blockbuster innovative drugs and devices, and based on the products of the public eye care ecosystem", continuously strengthen the influence of the industry, and achieve new breakthroughs in the business field. The Group always puts focus on the business field. The Group also puts focus on the development strategy of the global innovative ophthalmic drug drug R&D and the global innovative ophthalmic Drug R&D and the Group's global innovative Ophthalmic drug R&D and GPN00884 eye drops will be available in China.